[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112016015422A2 - formulações de vacina de frasco único - Google Patents

formulações de vacina de frasco único

Info

Publication number
BR112016015422A2
BR112016015422A2 BR112016015422A BR112016015422A BR112016015422A2 BR 112016015422 A2 BR112016015422 A2 BR 112016015422A2 BR 112016015422 A BR112016015422 A BR 112016015422A BR 112016015422 A BR112016015422 A BR 112016015422A BR 112016015422 A2 BR112016015422 A2 BR 112016015422A2
Authority
BR
Brazil
Prior art keywords
single vial
vaccine formulations
vial vaccine
lyophilized formulations
formulations
Prior art date
Application number
BR112016015422A
Other languages
English (en)
Inventor
B Fox Christopher
Barnes V Lucien
M Kramer Ryan
G Reed Steven
S Vedvick Thomas
Original Assignee
Infectious Disease Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectious Disease Res Inst filed Critical Infectious Disease Res Inst
Publication of BR112016015422A2 publication Critical patent/BR112016015422A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

resumo "formulações de vacina de frasco único" a presente invenção refere-se a formulações liofilizadas termoestáveis, incluindo vacinas e composições farmacêuticas para induzir ou intensificar uma resposta imune, e métodos de utilização das mesmas. as formulações liofilizadas geralmente compreendem um antígeno e/ou um adjuvante, um óleo metabolizável e um excipiente de formação de torta.
BR112016015422A 2013-12-31 2014-12-29 formulações de vacina de frasco único BR112016015422A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361922761P 2013-12-31 2013-12-31
PCT/US2014/072615 WO2015103167A2 (en) 2013-12-31 2014-12-29 Single vial vaccine formulations

Publications (1)

Publication Number Publication Date
BR112016015422A2 true BR112016015422A2 (pt) 2017-10-24

Family

ID=53494219

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016015422A BR112016015422A2 (pt) 2013-12-31 2014-12-29 formulações de vacina de frasco único

Country Status (15)

Country Link
US (2) US11801223B2 (pt)
EP (2) EP3915579A1 (pt)
JP (1) JP6741580B2 (pt)
KR (3) KR102411781B1 (pt)
CN (1) CN106163551A (pt)
AU (2) AU2014373928C1 (pt)
BR (1) BR112016015422A2 (pt)
CA (1) CA2935620A1 (pt)
EA (1) EA201691348A1 (pt)
ES (1) ES2880306T3 (pt)
IL (2) IL310015A (pt)
MX (2) MX2016008640A (pt)
PT (1) PT3089754T (pt)
WO (1) WO2015103167A2 (pt)
ZA (1) ZA201604498B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3915579A1 (en) 2013-12-31 2021-12-01 Infectious Disease Research Institute Single vial vaccine formulations
JP6893765B2 (ja) * 2016-07-15 2021-06-23 森山　雅美 人以外の陸上動物用のウイルス感染症に対する抗体誘導剤とその補助剤
JOP20200140A1 (ar) * 2017-12-07 2022-10-30 Merck Sharp & Dohme صيغ لتركيبات لقاح فيروس حُمى الضنك
KR102154572B1 (ko) * 2017-12-14 2020-09-10 연세대학교 산학협력단 Rv3628/Rv0351을 포함하는 새로운 BCG prime booster 백신 조성물
CN108823232A (zh) * 2018-04-20 2018-11-16 中国科学院广州生物医药与健康研究院 一种艾滋病疫苗及其制备方法
CN110787291A (zh) * 2018-08-03 2020-02-14 王元涛 一种加强型佐剂
WO2020081668A2 (en) * 2018-10-19 2020-04-23 Genentech, Inc. Defect detection in lyophilized drug products with convolutional neural networks
WO2020109365A1 (en) * 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
TW202103731A (zh) * 2019-02-27 2021-02-01 日商富士軟片股份有限公司 微針陣列及微針陣列之製造方法
EP3976092A1 (en) 2019-05-25 2022-04-06 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US20240050561A1 (en) 2020-12-23 2024-02-15 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4420558A (en) 1981-02-12 1983-12-13 Janssen Pharmaceutica N.V. Bright field light microscopic method of enumerating and characterizing subtypes of white blood cells and their precursors
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4420461A (en) 1982-05-26 1983-12-13 Ortho Diagnostic Systems Inc. Agglutination-inhibition test kit for detecting immune complexes
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4743540A (en) 1983-09-27 1988-05-10 Memorial Sloan-Kettering Cancer Center Method for diagnosis of subclassifications of common varied immunodeficiency disease group
US5147785A (en) 1983-11-01 1992-09-15 Amtl Corporation Method and apparatus for measuring the degree of reaction between a foreign entity and white blood cells
US4614722A (en) 1983-11-01 1986-09-30 Pasula Mark J Method and apparatus for measuring the degree of reaction between antigens and leukocyte cellular antibodies
US4595654A (en) 1983-11-07 1986-06-17 Immunomedics Inc. Method for detecting immune complexes in serum
US4659659A (en) 1985-01-22 1987-04-21 Monsanto Company Diagnostic method for diseases having an arthritic component
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US5310651A (en) 1986-01-22 1994-05-10 Institut Pasteur DNA probes of human immunodeficiency virus type 2 (HIV-2), and methods employing these probes for dectecting the presence of HIV-2
US6514691B1 (en) 1986-01-22 2003-02-04 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2
US5976785A (en) 1986-01-22 1999-11-02 Institut Pasteur Competitive assays for determining the effectiveness of a human immunodeficiency virus type 2 (HIV-2) antiviral agent, employing peptides and proteins of HIV-2
US6054565A (en) 1986-03-03 2000-04-25 Institut Pasteur Nucleic Acids of HIV-2, Diagnostic Test Kit and Method using Nucleic Acid Probes of HIV-2
FR2672290B1 (fr) 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
US5565209A (en) 1987-03-17 1996-10-15 Akzo Nobel N.V. Adjuvant mixture
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US5231168A (en) 1988-09-16 1993-07-27 Statens Seruminstitut Malaria antigen
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
ATE205534T1 (de) 1988-12-16 2001-09-15 Nederlanden Staat Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
DE69031556T2 (de) 1989-07-25 1998-05-14 Smithkline Beecham Biologicals S.A., Rixensart Antigene sowie Verfahren zu deren Herstellung
US4981684A (en) 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US5298396A (en) 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5124141A (en) 1990-06-14 1992-06-23 Flow Incorporated Method for diagnosing malaria
US5162990A (en) 1990-06-15 1992-11-10 The United States Of America As Represented By The United States Navy System and method for quantifying macrophage phagocytosis by computer image analysis
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
DE69133042T2 (de) 1990-11-06 2003-01-30 Nippon Shinyaku Co Ltd Lyophilisierte zubereitung sowie deren herstellung
DE122007000019I1 (de) 1991-07-19 2007-07-26 Univ Queensland Impfstoffen gegen Papillomavirus
DE69228698T2 (de) 1991-11-16 1999-09-16 Smithkline Beecham Biologicals S.A., Rixensart HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG
JPH05328975A (ja) 1992-06-02 1993-12-14 Takara Shuzo Co Ltd Ｅ１ａ−ｆ遺伝子
DE122007000094I1 (de) 1992-06-25 2008-03-27 Papillomavirus vakzine
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5411865A (en) 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies
DE69435331D1 (de) 1993-03-09 2011-02-03 Univ Rochester Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5532133A (en) 1993-06-02 1996-07-02 New York University Plasmodium vivax blood stage antigens, PvESP-1, antibodies, and diagnostic assays
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
JPH11504801A (ja) 1994-10-07 1999-05-11 ラッツ ギッスマン パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DE69633272T2 (de) 1995-02-08 2005-09-08 Takara Bio Inc., Otsu Methoden zur Krebsbehandlung und -kontrolle
CA2211995A1 (en) 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5912166A (en) 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5846758A (en) 1995-11-30 1998-12-08 His Excellency Ghassan I. Shaker Method for diagnosing autoimmune diseases
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
SE9600648D0 (sv) 1996-02-21 1996-02-21 Bror Morein Receptorbimdande enhet
ATE229073T1 (de) 1996-09-06 2002-12-15 Univ California Protein e25a, methoden zu dessen herstellung und anwendung
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6887660B2 (en) 1997-02-25 2005-05-03 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP2050465B1 (en) 1997-08-29 2014-06-11 Antigenics Inc. Compositions comprising the adjuvant QS-21 and polysorbate or cyclodextrin as excipient
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
KR100769103B1 (ko) 1997-11-28 2007-10-23 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
US7012134B2 (en) 1998-01-26 2006-03-14 Human Genome Sciences, Inc. Dendritic enriched secreted lymphocyte activation molecule
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
NZ506086A (en) 1998-02-05 2003-01-31 Smithkline Beecham Biolog S Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins, antigens comprising derivatised thiol residues and of compositions for vaccination
US6596501B2 (en) 1998-02-23 2003-07-22 Fred Hutchinson Cancer Research Center Method of diagnosing autoimmune disease
IL137998A0 (en) 1998-03-09 2001-10-31 Smithkline Beecham Biolog Combined vaccine compositions
KR100797876B1 (ko) 1998-04-07 2008-01-24 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
JP2002511266A (ja) 1998-04-15 2002-04-16 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 腫瘍関連核酸及びその使用
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
EP1870466A3 (en) 1998-07-14 2008-03-19 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US6512102B1 (en) 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US6630169B1 (en) * 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
US6919210B1 (en) 1999-04-07 2005-07-19 Hiroshi Okamoto Method for identifying autoimmune disease, method for detecting anti-Reg protein autoantibody and diagnostics for autoimmune disease
EP1187629B1 (en) 1999-04-19 2004-09-22 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US20020064801A1 (en) 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
US6587792B1 (en) 2000-01-11 2003-07-01 Richard A. Thomas Nuclear packing efficiency
EP1122542A1 (en) 2000-02-01 2001-08-08 Anda Biologicals S.A. Method for the rapid detection of whole microorganisms on retaining membranes by use of chaotropic agents
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
GB0020089D0 (en) * 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US6855322B2 (en) 2001-01-26 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Isolation and purification of P. falciparum merozoite protein-142 vaccine
US6893820B1 (en) 2001-01-31 2005-05-17 The Ohio State University Research Foundation Detection of methylated CpG rich sequences diagnostic for malignant cells
EP1423405A4 (en) 2001-03-26 2005-01-05 Us Army AMA-1 PROTEIN OF PLASMODIUM FALCIPARUM AND ITS APPLICATIONS
US7029685B2 (en) 2001-03-26 2006-04-18 The United States Of America As Represented By The Secretary Of The Army Plasmodium falciparum AMA-1 protein and uses thereof
US6933123B2 (en) 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
AU2002339865A1 (en) 2001-09-05 2003-03-18 The Children's Hospital Of Philadelphia Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
DE102005032175A1 (de) 2005-07-09 2007-01-18 Krones Ag Behälter-Behandlungsmaschine und Verfahren zum Laden und Entladen einer Behälter-Behandlungsmaschine
EP1611926B1 (de) 2005-07-19 2008-01-16 Gebrüder Holzapfel GmbH & Co. KG Auftriebshilfe
FR2896162B1 (fr) * 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
EP2468300B1 (en) * 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
JP5419709B2 (ja) * 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
EP3199176B1 (en) 2007-04-04 2020-02-19 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
CL2008001491A1 (es) * 2007-05-24 2008-11-28 Glaxosmithkline Biolog Sa Composicion liofilizada que comprende uno o mas antigenos y un agonista del receptor de tipo toll 9 (tlr9); y procedimiento de preparacion.
US8916168B2 (en) 2007-07-13 2014-12-23 Infectious Disease Research Institute Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis
KR100875856B1 (ko) 2007-10-04 2008-12-26 암페놀피닉스 주식회사 휴대전화기용 스윙힌지
EP2254554A1 (en) * 2008-02-25 2010-12-01 Novavax, Inc. Sugar glassified virus like particles (vlps)
EP2300051B1 (en) 2008-05-21 2014-11-12 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
US8410258B2 (en) 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
AR073452A1 (es) 2008-07-03 2010-11-10 Infectious Disease Res Inst Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis
US8793881B2 (en) 2008-08-15 2014-08-05 Stanley Black & Decker, Inc. Utility knife with blade lock
MX2011012836A (es) 2009-06-05 2012-04-20 Infectious Disease Res Inst Adyuvantes sinteticos de glucopiranosil-lipido.
RU2012144612A (ru) * 2010-04-15 2014-05-20 Син Ниппон Байомедикал Лэборэтэриз, Лтд. Способ и композиции для интраназальной доставки
US20120114688A1 (en) 2010-11-08 2012-05-10 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
CA2819120C (en) 2010-12-22 2016-07-05 Wyeth Llc Stable immunogenic compositions of staphylococcus aureus antigens
EP2709657B1 (en) * 2011-05-17 2018-10-24 Soligenix, Inc. Thermostable vaccine compositions and methods of preparing same
JP6120839B2 (ja) 2011-07-06 2017-04-26 ノバルティス アーゲー カチオン性水中油型エマルジョン
DK2811981T3 (da) * 2012-02-07 2019-06-11 Infectious Disease Res Inst Forbedrede adjuvansformuleringer, der omfatter tlr4-agonister, og fremgangsmåder til anvendelse heraf
JP2015519348A (ja) 2012-05-23 2015-07-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ インフルエンザワクチン構築物
KR20150034170A (ko) * 2012-06-25 2015-04-02 이머전트 프로덕트 디벨롭먼트 게이더스버그 인코포레이티드 온도 안정성 백신 제형
JP5328975B2 (ja) 2012-12-19 2013-10-30 ルネサスエレクトロニクス株式会社 Ｒｆパワーモジュール
EP3915579A1 (en) 2013-12-31 2021-12-01 Infectious Disease Research Institute Single vial vaccine formulations

Also Published As

Publication number Publication date
IL246456B2 (en) 2024-06-01
JP2017502962A (ja) 2017-01-26
KR20220100041A (ko) 2022-07-14
CN106163551A (zh) 2016-11-23
EP3089754A4 (en) 2017-08-02
EP3089754B1 (en) 2021-04-21
IL310015A (en) 2024-03-01
US20160324783A1 (en) 2016-11-10
ZA201604498B (en) 2019-10-30
WO2015103167A2 (en) 2015-07-09
IL246456B1 (en) 2024-02-01
AU2014373928A1 (en) 2016-07-21
EA201691348A1 (ru) 2016-11-30
AU2014373928B2 (en) 2020-07-16
EP3089754A2 (en) 2016-11-09
AU2020227042A1 (en) 2020-09-17
KR102411781B1 (ko) 2022-06-22
MX2022002106A (es) 2022-03-17
MX2016008640A (es) 2016-10-07
ES2880306T3 (es) 2021-11-24
KR20160133413A (ko) 2016-11-22
EP3915579A1 (en) 2021-12-01
JP6741580B2 (ja) 2020-08-19
CA2935620A1 (en) 2015-07-09
IL246456A0 (en) 2016-08-31
AU2014373928C1 (en) 2020-12-17
US20230293440A1 (en) 2023-09-21
WO2015103167A3 (en) 2015-11-12
PT3089754T (pt) 2021-07-23
AU2020227042B2 (en) 2021-12-02
US11801223B2 (en) 2023-10-31
KR20240023713A (ko) 2024-02-22

Similar Documents

Publication Publication Date Title
BR112016015422A2 (pt) formulações de vacina de frasco único
BR112018012873A2 (pt) vacina de vírus zika
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EA201790239A1 (ru) Молекула-носитель для антигенов
UY36006A (es) Construcciones de proteína uspa2 y usos de las mismas.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
BR112017005231A2 (pt) formulações eutéticas de cloridrato de ciclobenzaprina
EA201892735A1 (ru) Состав вакцины против hiv
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
BR112015019283A2 (pt) composições e métodos de aprimoramento de respostas imunes à eiméria ou infecção por eiméria limitadora
BR112017002440A2 (pt) vírus da diarreia epizoótica porcina mutante para utilização em uma vacina
BR112015023738B8 (pt) Vacinas de nucleoproteina influenza
BR112016028418A2 (pt) composição de adjuvante, vacina, anticorpo agonista cd40 ou uma parte desse, composição farmacêutica, construto, célula, e, método de mapeamento de epítopo de um polipeptídeo
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
EA201892003A1 (ru) Лечение атопического дерматита собак
DK3016673T3 (da) Pattedyrsmælkeosteopontin til forbedring af immunreaktion
PH12014502015B1 (en) Novel veterinary vaccine
BR112014023283A8 (pt) Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza
BR112018002107A2 (pt) resposta imune potencializada em espécies suínas
BR112017002206A2 (pt) peptídeo derivado de koc1 e vacina incluindo o mesmo
AR106501A1 (es) Adyuvante y composición de vacuna que lo contiene
BR112017028052A2 (pt) peptídeo, método para induzir uma resposta imune em um sujeito e formulação de vacina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ACCESS TO ADVANCED HEALTH INSTITUTE (US)

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]